|
Current issue
Archive
Manuscripts accepted
About the journal
Editorial board
Abstracting and indexing
Contact
Instructions for authors
Ethical standards and procedures
Editorial System
Submit your Manuscript
 
|
1/2025
vol. 100 abstract:
Review paper
Does corticosteroid treatment affect the progression of pediatric IgA nephropathy – a systematic review and meta-analysis
Bebby Shelby
1
,
Cynthia Cynthia
2
,
Wida Ratna Sari
3
,
Erika Aini Putri
4
,
Yoga Eka Prayuda
5
,
Aditya Primadana
6
,
Andro Pramana Witarto
7
Pediatr Pol 2025; 100 (1): 74-85
Online publish date: 2025/03/14
View
full text
Get citation
ENW EndNote
BIB JabRef, Mendeley
RIS Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
Immunoglobulin A nephropathy (IgAN) is an autoimmune disease in pediatric patients, with corticosteroid (CS) treatment remaining controversial. This meta-analysis evaluates the efficacy and safety of CS in pediatric IgAN patients. A systematic search of PubMed, ProQuest, and Wiley identified six studies with 208 patients. Outcomes included estimated glomerular filtration rate (eGFR), events of renal insufficiency, end-stage renal disease (ESRD), proteinuria, hematuria, IgA deposits, and side effects. Corticosteroid treatment showed a significant increase in eGFR (mean differences – MD: 11.84 [0.73–22.95] ml/min/1.73 m2), lower odds of having ESRD (odds ratios – OR: 0.21 [0.05–0.94]) and heavy proteinuria (OR: 0.15 [0.04–0.57]), and significant reduction in dipstick hematuria (MD: 2.89 [–3.85 to –1.93]). However, IgA deposits persisted despite CS treatment. Corticosteroid side effects were minimal. Corticosteroids may reduce glomerular damage and preserve renal function in pediatric IgAN patients, but limitations in addressing IgA deposits suggest the need for additional therapies.
keywords:
IgA nephropathy, pediatric, meta-analysis, treatment, corticosteroid |
POLSKI
